Summary:
Randomized, double-blind, stratified, parallel-group, multicenter study, 26 weeks in duration, that is designed to evaluate the non-inferiority of fluticasone propionate/salmeterol combination versus fluticasone propionate on the composite endpoint of serious asthma outcomes (asthma-related hospitalization, endotrachealintubation, and death) in subjects with asthma.
Qualified Participants Must:
• Be 12 years of age and older
•
Be appropriately using treatment for asthma
•
Be diagnosed with asthma for at least 1 year prior to study enrolment
•
Have the ability to answer questions regarding asthma status and quality of life and ability to use a daily electronic data capture system
•
Have the ability to demonstrate proper use of a metered-dose inhaler and dry powder inhaler (DPI) device
Qualified Participants May Receive:
All patient care and medications related to the study(No placebo medication will be provide). Compensation for time and travel for those who qualified.